Evidence map›Paper›PMID 40263566›Full record

ArticleScientific reports2025

A DFT investigation of the adsorption mechanism of paclitaxel on functionalized graphene oxide for enhanced drug delivery.

Bader Huwaimel, Saad Alqarni

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bader HuwaimelDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Hail, 55473, Saudi Arabia. b.huwaimel@uoh.edu.sa.
Saad AlqarniDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Hail, 55473, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of effective drug delivery systems is vital for enhancing the therapeutic efficacy of anticancer agents, particularly paclitaxel (PTX). Despite its potent anticancer properties, PTX faces limitations due to poor solubility and non-specific distribution, leading to significant side effects. To address these challenges, researchers have explored the use of reduced graphene oxide (rGO) as a nanocarrier. Functionalized rGO exhibits unique physicochemical properties, including high surface area and biocompatibility, which enhance drug loading capacity. This study investigates the adsorption mechanisms of PTX on various functionalized rGO surfaces, utilizing computational methods such as Density Functional Theory and Molecular Dynamics simulations. The results demonstrate that functionalization with hydroxyl (-OH), carboxyl (-COOH), and sulfonic (-SO) groups significantly influences the adsorption energy and charge transfer characteristics of PTX on GO. The adsorption energies calculated for PTX@rGO-OH and PTX@rGO-COOH were found to be -0.76 eV and - 0.91 eV, respectively, indicating physisorption predominantly through hydrogen bonding. In contrast, PTX@rGO-SO exhibited a higher adsorption energy of -2.09 eV, suggesting chemisorption facilitated by stronger covalent interactions. The presence of these functional groups also enhanced the binding affinity and stability of the drug-nanocarrier complex. Charge transfer analysis revealed that the rGO-COOH and rGO-SO systems exhibited significant changes in electronic properties, with charge transfers estimated at -0.16e and - 0.08e, respectively. These results indicate enhanced electronic coupling between PTX and the functionalized rGO surfaces, which can improve drug loading efficiency and release kinetics. The study also highlights the importance of optimizing surface chemistry to maximize drug interactions, leading to improved therapeutic outcomes. In conclusion, the investigation underscores the potential of functionalized graphene oxide as a promising platform for drug delivery systems. The findings, including the adsorption energies and charge transfer data, provide valuable insights into the interactions between PTX and functionalized rGO, paving the way for the design of optimized nanocarriers capable of enhancing the efficacy of anticancer therapies. The continued exploration of these systems is essential for advancing the field of nanomedicine and improving treatment strategies for cancer patients.

Indexed as

Drug Delivery SystemsGraphitePaclitaxelAdsorptionAntineoplastic Agents, PhytogenicDensity Functional TheoryDrug CarriersMolecular Dynamics SimulationAntineoplastic Agents, PhytogenicDrug Carriersgraphene oxideGraphitePaclitaxelDFTDrug deliveryFunctionalized graphene oxideMolecular dynamicsPaclitaxel

Identifiers

PMID40263566
PMCPMC12015527

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.